Participated · Seed · Jan 2026

EncephalX is a Sherbrooke-based medical technology venture focused on redefining post-trauma and post-stroke cranial care through its flagship Dynamic Cranioplasty System (DCPS). The DCPS replaces the current two-stage craniectomy/cranioplasty workflow with a single operation that offers continuous intracranial pressure decompression, aiming to improve patient outcomes and shorten hospital stays. The technology originated from academic research into cranial defects and has been refined in close collaboration with practicing neurosurgeons, including the company’s medical director, Dr. Christian Iorio-Morin. Management plans to use its newly raised capital to achieve the first-in-human implantation and advance regulatory approval of the fully developed surgical kit. Longer-term goals include building additional clinical, regulatory, and industrial partnerships and expanding the platform internationally. No revenue or user metrics have been disclosed to date.

Led · Seed · Mar 2024

RetinaLogik is a Calgary-based startup that has developed a VR-AI-powered platform and portable headset for eye care. The system enables essential tests, including visual field exams, while streamlining the testing process to improve patient comfort and clinic efficiency. The device is ISO-13485 and MDSAP certified and is FDA registered; it has received Health Canada Class II medical device approval. RetinaLogik says the system can reduce upfront equipment costs by up to 90% compared with traditional equipment and includes multilingual support to bridge clinic communication gaps. The company completed a $1.1M funding round and received support from investors and community partners. RetinaLogik plans to expand adoption across North America and beyond to close critical gaps in eye care, enable earlier detection and treatment, and prevent irreversible vision loss. RetinaLogik’s core product is a portable eye-test platform that uses a virtual reality headset and AI-driven analytics to collect and analyze visual field data. While wearing the headset, patients are guided through a tutorial in their own language and perform vision tests whose results can be reviewed remotely by specialists. The device is already deployed in clinics across Canada and has been used in partnerships to deliver testing in senior homes. Co‑founders Abdullah Sarhan and Julia St.Amand began work on the project in 2018 and built the first prototype in 2019 after years of iteration and clinic testing. With new funding, the company plans to scale its team, add new vision tests, support device sales, and pursue Class 2 certification from Health Canada. To date RetinaLogik has raised CA$1.7M in total funding, including the recent CA$783,000 pre‑seed round.

Participated · Equity · Sep 2021

Bird & Be offers direct-to-consumer, personalized at-home kits designed to optimize fertility outcomes for people with sperm and eggs. The company optimizes care through two pillars: Education (content and patented early screening diagnostics) and Action (custom supplements, prescriptions and a referral network). Bird & Be introduced its signature line of supplements in July. It plans to launch at-home tools this fall, including a patent-pending urine stick Ovarian Reserve test, pregnancy, ovulation and sperm tests. The company aims to break down barriers to access via information, affordable products, and digitizing basic protocols to accelerate time to care. Bird & Be announced a $1.8M financing round led by BAM Ventures.